Bain Capital reports 7 million shares plus warrants in ADC Therapeutics (ADCT).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Bain Capital Life Sciences Opportunities IV, L.P. has reported a beneficial ownership of 14,825,625 common shares, or 9.99%, in ADC Therapeutics SA (ADCT) as of October 22, 2026. This includes 7,000,000 common shares and pre-funded warrants allowing the purchase of up to 22,703,927 common shares, though a 9.99% beneficial ownership blocker limits the exercisable amount.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.